Laurence Krieger Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Payer acceptability of metastasis-free survival as the primary endpoint in non-metastatic castration-resistant prostate cancer — Poster Session 2
• The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) — Poster Session 1